This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Laakso, M. Search for Related Content Social Bookmarking                         What's this?

Insulin resistance and cardiovascular disease

Department of Medicine, University of Kuopio, Kuopio 70210, Finland, markku.laakso{at}kuh.fi

Insulin resistance is characterised by a decreased rate of insulin-mediated glucose uptake and is associated with adverse changes in cardiovascular risk factors, such as high triglyceride levels, low levels of high-density lipoprotein cholesterol, raised blood pressure, obesity and increased levels of plasminogen activator inhibitor 1. The term `insulin resistance syndrome' (IRS) is used to describe the complex of factors associated with insulin resistance that is found in patients both with and without type 2 diabetes. Although the presence of insulin resistance syndrome is generally considered to be a risk factor for cardiovascular disease, there is a lack of definitive evidence for a causal link. Recently, however, a statistical method known as factor analysis has been applied to the cluster of cardiovascular risk factors associated with IRS. This has been able to show that the `insulin resistance factor' (high plasma insulin and glucose levels, body mass index, waist-to-hip ratio and triglyceride levels) predicted coronary heart disease events in elderly non-diabetic men as well as in patients with type 2 diabetes. Therefore, treatment of insulin resistance whether by pharmacological (eg. thiazolidinediones) or nonpharmacological means has the potential to offer both improvements in glycaemic control and in cardiovascular events.

Key Words: diabetes • cardiovascular disease • cluster analysis • insulin resistance • lipid metabolism.

References

• Wilson PWF, Cupples AD, Kannel WB Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991;2:586-90.
• Stamler J., Vaccaro O., Neaton JD, Wentworth D. for the MRFIT Research Group. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.[Abstract]
• Kannel WB, McGee DL Diabetes and cardiovascular disease: The Framingham Study. JAMA 1979;241:2035-8.[Abstract/Free Full Text]
• Haffner SM, Lehton S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Saydah SH, Loria CM, Eberhardt MS, Brancati FL Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;24: 447-53.[Abstract/Free Full Text]
• Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24: 683-9.[Abstract/Free Full Text]
• Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. UK Prospective Diabetes Study Group. Diabetologia 1991:34:877-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Turner NC, Clapham JC Insulin resistance, impaired glucose tolerance and non-insulin dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res 1998; 51:36-94.
• Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.[Abstract]
• Reaven GM Insulin resistance and its consequences: non-insulin-dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM (eds.). Diabetes Mellitus. Philadelphia: Lippincott-Raven, 1996;509-19.
• Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998;97:996-1001.[Abstract/Free Full Text]
• Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-65.[Abstract/Free Full Text]
• Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000; 43:148-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lempiäinen P., Mykkänen L., Pyörälä K., Laakso M., Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly non-diabetic men. Circulation 1999;100:123-8.[Abstract/Free Full Text]
• Kuusisto J., Lempiänen P., Mykkänen L., Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly Type 2 diabetic men. Diabetes Care 2001;24:1629-33.[Abstract/Free Full Text]
• Sowers J., Sowers P., Peuler J. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994;123:647-52.[Web of Science][Medline] [Order article via Infotrieve]
• Agewall S. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk. J Intern Med 1999;246:489-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Eliasson M., Asplund K., Evrin PE et al. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 1994;43:1579-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brunetti P. Pioglitazone: current profile. Br J Diabetes Vasc Dis 2002;2(suppl 1):S16-S21.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S9-S11 (2002)
DOI: 10.1177/14746514020020010301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Laakso, M. Search for Related Content Social Bookmarking                         What's this?